News
HIND
1.890
-1.56%
-0.030
Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591
PUBT · 4d ago
Vyome signs exclusive license agreement with Impetis
TipRanks · 4d ago
Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors
PUBT · 4d ago
VYOME HOLDINGS INC - RECEIVES EXCLUSIVE LICENSE FOR SELECTIVE JAK 1/3 AND JAK1 INHIBITORS
Reuters · 4d ago
Weekly Report: what happened at HIND last week (0504-0508)?
Weekly Report · 5d ago
Weekly Report: what happened at HIND last week (0427-0501)?
Weekly Report · 05/04 09:54
Vyome Holdings Shareholders Tighten Capital Structure at Meeting
TipRanks · 04/29 22:07
Vyome Holdings shareholders approve cut in authorized common shares to 50 million
PUBT · 04/29 21:01
Weekly Report: what happened at HIND last week (0420-0424)?
Weekly Report · 04/27 09:56
Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market
TipRanks · 04/23 17:35
Vyome Holdings presents Phase 2 study results on VT-1953
TipRanks · 04/22 12:37
Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting
Benzinga · 04/22 12:05
Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR
PUBT · 04/22 12:03
Weekly Report: what happened at HIND last week (0413-0417)?
Weekly Report · 04/20 09:53
Weekly Report: what happened at HIND last week (0406-0410)?
Weekly Report · 04/13 09:56
Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026
TipRanks · 04/06 12:44
Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR
Benzinga · 04/06 12:06
Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026
Reuters · 04/06 12:00
Weekly Report: what happened at HIND last week (0330-0403)?
Weekly Report · 04/06 09:56
More
Webull provides a variety of real-time HIND stock news. You can receive the latest news about Vyome Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HIND
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.